A practical approach to genetic testing for von Willebrand disease

Mayo Clinic Proceedings

Volumn 81, Issue 5, 2006, Pages 679-691

  Pruthi, Rajiv K ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR;

BLEEDING DISORDER; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC PROCEDURES; HUMAN; LABORATORY DIAGNOSIS; REVIEW; VON WILLEBRAND DISEASE;

EID: 33646422764     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.5.679     Document Type: Article

References (93)

1. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351:683-694.
2. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost. 1999;82:165-174.
3. Lorentz CP, Wieben ED, Tefferi A, Whiteman DAH, Dewald GW. Primer on medical genomics, part I: history of genetics and sequencing of the human genome. Mayo Clin Proc. 2002;77:773-782.
4. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005;3:2619-2626.
5. Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med. 1995;155:1409-1415.
6. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
7. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059-41063.
8. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol. 2001;14:257-279.
9. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173-191.
10. Nilsson IM. Von Willebrand's disease-fifty years old. Annu Med Scand. 1977;201:497-508.
11. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69:454-459.
12. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123:893-898.
13. Weiss HJ, Ball AP, Mannucci PM. Incidence of severe von Willebrand's disease [letter]. N Engl J Med. 1982;307:127.
14. Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor, I: prevalence of severe von Willebrand's disease in western Europe and Israel. Br J Haematol. 1984;57:163-169.
15. von Willebrand E. Hereditär pseudohemofili. Finska Lakaresallsk Handl. 1926;5:7-112.
16. Holmberg L, Nilsson IM. Genetic variants of von Willebrand's disease. Br Med J. 1972;3:317-320.
17. Ruggeri ZM. Classification of von Willebrand disease. In: Verstraete M, Vermylen J, Lijnen R, Arnout J, eds. Thrombosis and Haemostasis. Leuven, Belgium: Leuven University Press; 1987:419-445.
18. Sadler JE, Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. A revised classification of von Willebrand disease. Thromb Haemost. 1994;71:520-525.
19. Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Best Pract Res Clin Haematol. 2001;14:281-298.
20. Favaloro EJ. Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder. Best Pract Res Clin Haematol. 2001;14:299-319.
21. Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia. 2004;10:199-217.
22. Quiroga T, Goycoolea M, Munoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients [published correction appears in J Thromb Haemost. 2005;3:622]. J Thromb Haemost. 2004;2:892-898.
23. Sadler JE, Rodeghiero F, ISTH SSC Subcommittee on von Willebrand Factor. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost. 2005;3:775-777.
24. Preston FE. Assays for von Willebrand factor functional activity: a UK NEQAS survey [letter] [published correction appears in Thromb Haemost. 1999;81:478]. Thromb Haemost. 1998;80:863.
25. Riddell AF, Jenkins PV, Nitu-Whalley IC, McCraw AH, Lee CA, Brown SA. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haematol. 2002;116:187-192.
26. Federici AB, Canciani M, Goodeve A, et al. Collagen binding (VWF: CB) is less sensitive than ristocetin cofactor activity (VWF: RCo) in suggesting von Willebrand factor (VWF) molecular defects in patients with von Willebrand disease type 1: results from the European Multicenter MCMDM-IVWD study [abstract]. J Thromb Haemost. 2005;3(suppl 1). Abstract P0269.
27. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood. 1989;74:1591-1599.
28. Levy G, Ginsburg D. Getting at the variable expressivity of von Willebrand disease. Thromb Haemost. 2001;86:144-148.
29. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101:2089-2093.
30. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet. 1985;37:89-101.
31. Gul JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691-1695.
32. Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest. 1976;57:1618-1625.
33. Triplett DA. Laboratory diagnosis of von Willebrand's disease. Mayo Clin Proc. 1991;66:832-840.
34. Favaloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor, use of different assays car influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. Am J Clin Pathol. 1995;104:264-271.
35. Favaloro EJ, Aboud M, Arthur C. Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor. Am J Hematol. 2001;66:53-56.
36. Castaman G, Eikenboom JC, Missiaglia E, Rodeghiero F. Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect. Br J Haematol. 2000;108:876-879.
37. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus "variants." Blood. 1980;56:712-716.
38. Hambleton J. Diagnosis and incidence of inherited von Willebrand disease. Curr Opin Hematol. 2001;8:306-311.
39. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood. 1989;74:1997-2000.
40. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol. 1981;47:283-293.
41. Casonato A, Sartori MT, de Marco L, Girolami A. 1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia. Thromb Haemost. 1990;64:117-120.
42. McKeown LP, Connaghan G, Wilson O, Hansmann K, Merryman P, Gralnick HR. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease. Am J Hematol. 1996;51:158-163.
43. Pasi KJ, Collins PW, Keeling DM, et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia. 2004;10:218-231.
44. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost. 1987;58:1033-1036.
45. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. 2003;9:1-23.
46. Keeney S, Cumming AM. The molecular biology of von Willebrand disease. Clin Lab Haematol. 2001;23:209-230.
47. Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30:253-269.
48. Peake IR, Bowen D, Bignell P, et al. Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gens. Blood. 1990;76:555-561.
49. Mercier B, Gaucher C, Mazurier C. Characterisation of 98 alleles in 105 unrelated individuals in the F8VWF gene. Nucleic Acids Res. 1991;19:4800.
50. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation: relationship to factor VIII procoagulant activity and antigen content. J Clin Invest. 1973;52:2708-2716.
51. Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood. 1985;66:796-802.
52. Hubert L, Ribba A, Mazurier C, et al. In vitro expression of ten missense mutations in the VWF C-terminal domain identified in patients diagnosed with type 1 VWD: results from the MCMDM-IVWD study [abstract]. J Thromb Haemost. 2005;3(suppl 1). Abstract P0865.
53. Ribba A, Stepanian A, Habart D, et al. Two novel type 1 von Willebrand disease causing mutations (G160W and N166I) in the von Willebrand factor propeptide, identified in the European study MCMDM-1VWD, are responsible for multimerization and secretion defects [abstract]. J Thromb Haemost. 2005; 3(suppl 1). Abstract P0265.
54. Nichols WC, Ginsburg D. von Willebrand disease. Medicine (Baltimore). 1997;76:1-20.
55. Castaman G, Eikenboom JC, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999;82:1065-1070.
56. Nicolle AL, Talks KL, Hanley J. The genetics of bleeding disorders: a report on the UK Haemophilia Centre Doctors' Organisation annual scientific symposium, 10th October 2003. Haemophilia. 2004;10:390-396.
57. Zhang ZP, Lindstedt M, Falk G, Blomback M, Egberg N, Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet. 1992;51:850-858.
58. Eikenboom JC, Ploosvan Amstel HK, Reitsma PH, Briet E. Mutationsin severe, type III von Willebrand's disease in the Dutch population: candidate missense and nonsense mutations associated with reduced levels of von Willebrand factor messenger RNA. Thromb Haemost. 1992;68:448-454.
59. Mohlke KL, Nichols WC, Westrick RJ, et al. A novel modifier gene for plasma von Willebrand factor level maps to distal mouse chromosome 11. Proc Natl Acad Sci U S A. 1996;93:15352-15357.
60. Mohlke KL, Purkayastha AA, Westrick RJ, et al. MVWF, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell. 1999;96:111-120.
61. O'Brien LA, James PD, Othman M, et al. Founder von Willebrand factor haplotype associated with type l von Willebrand disease. Blood. 2003;102:549-557.
62. Eikenboom J, Van Marion V, Putter H, et al. Linkage analysis of von Willebrand disease type 1 phenotype, von Willebrand factor levels and bleeding symptoms with Von Willebrand factor gene locus in the European Multicenter MCMDM-1VWD study [abstract]. J Thromb Haemost. 2005; 3(suppl 1). Abstract OR279.
63. Berliner SA, Seligsohn U, Zivelin A, Zwang E, Sofferman G. A relatively high frequency of severe (type III) von Willebrand's disease in Israel. Br J Haematol. 1986;62:535-543.
64. Zhang ZP, Falk G, Blomback M, Egberg N, Anvret M. A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients. Hum Mol Genet. 1992;1:767-768.
65. Schneppenheim R, Krey S, Bergmann F, et al. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet. 1994;94:640-652.
66. Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest. 1987;79:1459-1465.
67. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem. 1992;267:4424-4430.
68. Batlle J, Lopez Fernandez MF, Campos M, et al. The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors. Blood. 1986;68:1207-1212.
69. Schneppenheim R, Budde U, Obser T, et al. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood. 2001;97:2059-2066.
70. Weiss HJ, Sussman II. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood. 1986;68:149-156.
71. Holmberg L, Berntorp E, Donner M, Nilsson IM. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood. 1986;68:668-672.
72. Miller JL. Platelet-type von Willebrand disease. Thromb Haemost. 1996;75:865-869.
73. Schneppenheim R, Federici AB, Budde U, et al. Von Willebrand disease type 2M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost. 2000;83:136-140.
74. Mazurier C, Meyer D, Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease-results of an international survey. Thromb Haemost. 1996;76:270-274.
75. Siguret V, Lavergne JM, Cherel G, et al. A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD): direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD. Hum Genet. 1994;93:95-102.
76. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol. 2002;116:350-356.
77. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343-349.
78. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: a single institution experience. Am J Hematol. 2003;72:243-247.
79. Federici AB, Rand JH, Bucciarelli P, et al, Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry [published correction appears in Thromb Haemost. 2000;84:739]. Thromb Haemost. 2000;84:345-349.
80. David JL, Gaspard UJ, Gillain D, Raskinet R, Lepot MR. Hemostasis profile in women taking low-dose oral contraceptives. Am J Obstet Gynecol. 1990;163(1, pt 2):420-423.
81. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost. 1984;52:176-182.
82. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol. 1998;105:314-321.
83. Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol. 1991;98:909-918.
84. Hansen JB, Olsen JO, Osterud B. Physical exercise enhances plasma levels of extrinsic pathway inhibitor (EPI). Thromb Haemost. 1990;64:124-126.
85. Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem. 1989;264:19514-19527.
86. Kouides PA BD, Kasper C, Lipton R, et al. Desmopressin use in type 2B von Willebrand disease in North America: a survey of members of the Hemophilia Research Society of North America [abstract]. Blood. 2002;100:2750a. Abstract 98a.
87. Kulkarni R, Lusher JM. Intracranial and extracranial hemorrhages in newboms with hemophilia: a review of the literature. J Pediatr Hematol Oncol. 1999;21:289-295.
88. Tefferi A, Wieben ED, Dewald GW, Whiteman DAH, Bernard ME, Spelsberg TC. Primer on medical genomics, part II: background principles and methods in molecular genetics. Mayo Clin Proc. 2002;77:785-808.
89. Genetic counseling. Am J Hum Genet. 1975;27:240-242.
90. Biesecker BB. Goals of genetic counseling. Clin Genet. 2001;60:323-330.
91. Hook CC, DiMagno EP, Tefferi A. Primer on medical genomics, part XIII: ethical and regulatory issues. Mayo Clin Proc. 2004;79:645-650.
92. Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol. 2001;14:365-379.
93. Maddox JM, Anderson JA, Plews D, Ludlam CA. Management of acquired von Willebrand's syndrome in a patient requiring major surgery. Haemophilia. 2005;11:633-637.